Pellkofer, Hannah Luise

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Neuroinflammation"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Jarius, Sven"],["dc.contributor.author","Pellkofer, Hannah"],["dc.contributor.author","Siebert, Nadja"],["dc.contributor.author","Korporal-Kuhnke, Mirjam"],["dc.contributor.author","Hümmert, Martin W."],["dc.contributor.author","Ringelstein, Marius"],["dc.contributor.author","Rommer, Paulus S."],["dc.contributor.author","Ayzenberg, Ilya"],["dc.contributor.author","Ruprecht, Klemens"],["dc.contributor.author","Klotz, Luisa"],["dc.contributor.author","Asgari, Nasrin"],["dc.contributor.author","Zrzavy, Tobias"],["dc.contributor.author","Höftberger, Romana"],["dc.contributor.author","Tobia, Rafik"],["dc.contributor.author","Buttmann, Mathias"],["dc.contributor.author","Fechner, Kai"],["dc.contributor.author","Schanda, Kathrin"],["dc.contributor.author","Weber, Martin"],["dc.contributor.author","Asseyer, Susanna"],["dc.contributor.author","Haas, Jürgen"],["dc.contributor.author","Lechner, Christian"],["dc.contributor.author","Kleiter, Ingo"],["dc.contributor.author","Aktas, Orhan"],["dc.contributor.author","Trebst, Corinna"],["dc.contributor.author","Rostasy, Kevin"],["dc.contributor.author","Reindl, Markus"],["dc.contributor.author","Kümpfel, Tania"],["dc.contributor.author","Paul, Friedemann"],["dc.contributor.author","Wildemann, Brigitte"],["dc.date.accessioned","2021-04-14T08:32:46Z"],["dc.date.available","2021-04-14T08:32:46Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1186/s12974-020-01824-2"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17535"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/84009"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","1742-2094"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e407"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Neurology"],["dc.bibliographiccitation.lastpage","e418"],["dc.bibliographiccitation.volume","94"],["dc.contributor.author","Ringelstein, Marius"],["dc.contributor.author","Harmel, Jens"],["dc.contributor.author","Zimmermann, Hanna"],["dc.contributor.author","Brandt, Alexander U."],["dc.contributor.author","Paul, Friedemann"],["dc.contributor.author","Haarmann, Axel"],["dc.contributor.author","Buttmann, Mathias"],["dc.contributor.author","Hümmert, Martin W."],["dc.contributor.author","Trebst, Corinna"],["dc.contributor.author","Schroeder, Christoph"],["dc.contributor.author","Ayzenberg, Ilya"],["dc.contributor.author","Kleiter, Ingo"],["dc.contributor.author","Hellwig, Kerstin"],["dc.contributor.author","Havla, Joachim"],["dc.contributor.author","Kümpfel, Tania"],["dc.contributor.author","Jarius, Sven"],["dc.contributor.author","Wildemann, Brigitte"],["dc.contributor.author","Rommer, Paulus"],["dc.contributor.author","Weber, Martin S."],["dc.contributor.author","Pellkofer, Hannah"],["dc.contributor.author","Röpke, Luise"],["dc.contributor.author","Geis, Christian"],["dc.contributor.author","Retzlaff, Nele"],["dc.contributor.author","Zettl, Uwe"],["dc.contributor.author","Deppe, Michael"],["dc.contributor.author","Klotz, Luisa"],["dc.contributor.author","Young, Kim"],["dc.contributor.author","Stellmann, Jan-Patrick"],["dc.contributor.author","Kaste, Matthias"],["dc.contributor.author","Kermer, Pawel"],["dc.contributor.author","Marouf, Wael"],["dc.contributor.author","Lauda, Florian"],["dc.contributor.author","Tumani, Hayrettin"],["dc.contributor.author","Graf, Jonas"],["dc.contributor.author","Klistorner, Alexander"],["dc.contributor.author","Hartung, Hans-Peter"],["dc.contributor.author","Aktas, Orhan"],["dc.contributor.author","Albrecht, Philipp"],["dc.date.accessioned","2020-12-10T18:41:46Z"],["dc.date.available","2020-12-10T18:41:46Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1212/WNL.0000000000008684"],["dc.identifier.eissn","1526-632X"],["dc.identifier.issn","0028-3878"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77670"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","14"],["dc.bibliographiccitation.journal","Journal of Neuroinflammation"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Jarius, Sven"],["dc.contributor.author","Ruprecht, Klemens"],["dc.contributor.author","Wildemann, Brigitte"],["dc.contributor.author","Kuempfel, Tania"],["dc.contributor.author","Ringelstein, Marius"],["dc.contributor.author","Geis, Christian"],["dc.contributor.author","Kleiter, Ingo"],["dc.contributor.author","Kleinschnitz, Christoph"],["dc.contributor.author","Berthele, Achim"],["dc.contributor.author","Brettschneider, Johannes"],["dc.contributor.author","Hellwig, Kerstin"],["dc.contributor.author","Hemmer, Bernhard"],["dc.contributor.author","Linker, Ralf A."],["dc.contributor.author","Lauda, Florian"],["dc.contributor.author","Mayer, Christoph A."],["dc.contributor.author","Tumani, Hayrettin"],["dc.contributor.author","Melms, Arthur"],["dc.contributor.author","Trebst, Corinna"],["dc.contributor.author","Stangel, Martin"],["dc.contributor.author","Marziniak, Martin"],["dc.contributor.author","Hoffmann, Frank"],["dc.contributor.author","Schippling, Sven"],["dc.contributor.author","Faiss, Juergen H."],["dc.contributor.author","Neuhaus, Oliver"],["dc.contributor.author","Ettrich, Barbara"],["dc.contributor.author","Zentner, Christian"],["dc.contributor.author","Guthke, Kersten"],["dc.contributor.author","Hofstadt-van Oy, Ulrich"],["dc.contributor.author","Reuss, Reinhard"],["dc.contributor.author","Pellkofer, Hannah L."],["dc.contributor.author","Ziemann, Ulf"],["dc.contributor.author","Kern, Peter"],["dc.contributor.author","Wandinger, Klaus-Peter"],["dc.contributor.author","Bergh, Florian Then"],["dc.contributor.author","Boettcher, Tobias"],["dc.contributor.author","Langel, Stefan"],["dc.contributor.author","Liebetrau, Martin"],["dc.contributor.author","Rommer, Paulus S."],["dc.contributor.author","Niehaus, Sabine"],["dc.contributor.author","Muench, Christoph"],["dc.contributor.author","Winkelmann, Alexander"],["dc.contributor.author","Zettl U, Uwe K."],["dc.contributor.author","Metz, Imke"],["dc.contributor.author","Veauthier, Christian"],["dc.contributor.author","Sieb, Joern P."],["dc.contributor.author","Wilke, Christian"],["dc.contributor.author","Hartung, Hans-Peter"],["dc.contributor.author","Aktas, Orhan"],["dc.contributor.author","Paul, Friedemann"],["dc.date.accessioned","2018-11-07T09:14:18Z"],["dc.date.available","2018-11-07T09:14:18Z"],["dc.date.issued","2012"],["dc.description.abstract","Background: The diagnostic and pathophysiological relevance of antibodies to aquaporin-4 (AQP4-Ab) in patients with neuromyelitis optica spectrum disorders (NMOSD) has been intensively studied. However, little is known so far about the clinical impact of AQP4-Ab seropositivity. Objective: To analyse systematically the clinical and paraclinical features associated with NMO spectrum disorders in Caucasians in a stratified fashion according to the patients' AQP4-Ab serostatus. Methods: Retrospective study of 175 Caucasian patients (AQP4-Ab positive in 78.3%). Results: Seropositive patients were found to be predominantly female (p < 0.0003), to more often have signs of co-existing autoimmunity (p < 0.00001), and to experience more severe clinical attacks. A visual acuity of <= 0.1 during acute optic neuritis (ON) attacks was more frequent among seropositives (p < 0.002). Similarly, motor symptoms were more common in seropositive patients, the median Medical Research Council scale (MRC) grade worse, and MRC grades <= 2 more frequent, in particular if patients met the 2006 revised criteria (p < 0.005, p < 0.006 and p < 0.01, respectively), the total spinal cord lesion load was higher (p < 0.006), and lesions >= 6 vertebral segments as well as entire spinal cord involvement more frequent (p < 0.003 and p < 0.043). By contrast, bilateral ON at onset was more common in seronegatives (p < 0.007), as was simultaneous ON and myelitis (p < 0.001); accordingly, the time to diagnosis of NMO was shorter in the seronegative group (p < 0.029). The course of disease was more often monophasic in seronegatives (p < 0.008). Seropositives and seronegatives did not differ significantly with regard to age at onset, time to relapse, annualized relapse rates, outcome from relapse (complete, partial, no recovery), annualized EDSS increase, mortality rate, supratentorial brain lesions, brainstem lesions, history of carcinoma, frequency of preceding infections, oligoclonal bands, or CSF pleocytosis. Both the time to relapse and the time to diagnosis was longer if the disease started with ON (p < 0.002 and p < 0.013). Motor symptoms or tetraparesis at first myelitis and > 1 myelitis attacks in the first year were identified as possible predictors of a worse outcome."],["dc.identifier.doi","10.1186/1742-2094-9-14"],["dc.identifier.isi","000300949700001"],["dc.identifier.pmid","22260418"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7222"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/27377"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1742-2094"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e1184"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Neurology"],["dc.bibliographiccitation.lastpage","e1196"],["dc.bibliographiccitation.volume","98"],["dc.contributor.author","Hümmert, Martin W."],["dc.contributor.author","Schöppe, Louisa M."],["dc.contributor.author","Bellmann-Strobl, Judith"],["dc.contributor.author","Siebert, Nadja"],["dc.contributor.author","Paul, Friedemann"],["dc.contributor.author","Duchow, Ankelien"],["dc.contributor.author","Pellkofer, Hannah"],["dc.contributor.author","Kümpfel, Tania"],["dc.contributor.author","Havla, Joachim"],["dc.contributor.author","Jarius, Sven"],["dc.contributor.author","Trebst, Corinna"],["dc.contributor.authorgroup","on behalf of the Neuromyelitis Optica Study Group (NEMOS)"],["dc.date.accessioned","2022-04-01T10:02:06Z"],["dc.date.available","2022-04-01T10:02:06Z"],["dc.date.issued","2022"],["dc.description.abstract","Background and Objectives To evaluate costs and health-related quality of life (HRQoL) of neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD). Methods In this multicenter cross-sectional study, data on consumption of medical and nonmedical resources and work ability were assessed via patient questionnaires. Costs were analyzed in Euros for 2018 from the societal perspective. HRQoL was captured by the EuroQoL Group 5 Dimension 5 Level Scale (EQ-5D-5L) questionnaire. Clinical data were retrieved from the Neuromyelitis Optica Study Group (NEMOS) database. Results Two hundred twelve patients (80% women, median age 50 [19–83] years, median disease duration 7 [0–43] years, median Expanded Disability Status Scale [EDSS] score 3.5 [0–8.5], 66% aquaporin-4 immunoglobulin G [IgG] positive, 22% MOG IgG positive, 12% double seronegative) were analyzed. The mean total annual per capita cost of illness accounted for €59,574 (95% CI 51,225–68,293 or US dollars [USD] 70,297, 95% CI 60,445–80,586), and the mean index value of the EQ-5D-5L was 0.693 (95% CI 0.65–0.73). The most important cost drivers were informal care costs (28% of total costs), indirect costs (23%), and drugs (16%), especially immunotherapeutics. Costs showed a positive correlation with disease severity (ρ = 0.56, 95% CI 0.45–0.65); in the EDSS score 6.5 to 8.5 subgroup, the mean annual costs were €129,687 (95% CI 101,946–160,336 or USD 153,031, 95% CI 120,296–189,196). The HRQoL revealed a negative correlation to disease severity (ρ = −0.69, 95% CI −0.76 to −0.61); in the EDSS score 6.5 to 8.5 subgroup, the EQ-5D-5L mean index value was 0.195 (95% CI 0.13–0.28). Neither antibody status nor disease duration influenced the total annual costs or HRQoL. Discussion These German data from the era without approved preventive immunotherapies show enormous effects of the diseases on costs and quality of life. An early and cost-effective therapy should be provided to prevent long-term disability and to preserve quality of life."],["dc.identifier.doi","10.1212/WNL.0000000000200052"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/105822"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.eissn","1526-632X"],["dc.relation.issn","0028-3878"],["dc.title","Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Disease"],["dc.title.alternative","CHANCE\n NMO\n Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]